Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249242 | 0.86 | CSF1R (0.36) | LIPEMGLLP2RX3P2RX2 | |
| SCHEMBL27246537 | 0.86 | LIPE (0.40) | CHRNB2CHRNA4LIPEMGLLP2RX3 | |
| Hydrochloric Acid SCHEMBL30328348 | 0.85 | CHRNB2 (0.42) | CHRNB2CHRNA4LIPEMGLLTRPV4 | |
| Hydrochloric Acid SCHEMBL30328795 | 0.80 | CHRNB2 (0.40) | CHRNB2CHRNA4LIPEMGLLTRPV4 | |
| SCHEMBL31307974 | 0.79 | LIPE (0.44) | CHRNB2CHRNA4LIPEMGLLAXL | |
| SCHEMBL25936181 | 0.79 | HCRTR1 (0.34) | P2RX3P2RX2SCN9A | |
| SCHEMBL31239665 | 0.79 | HCRTR1 (0.34) | P2RX3P2RX2SCN9A | |
| SCHEMBL21607026 | 0.78 | HRH1 (0.47) | CHRNB2CHRNA4LIPETRPV4AXL | |
| SCHEMBL25145865 | 0.78 | TRPV4 (0.40) | TRPV4 | |
| SCHEMBL18357736 | 0.78 | MAOA (0.41) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | CHRNB2 1153/4885CHRNA4 346/4885LIPE 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.